Ascentage Pharma Group International (NASDAQ:AAPG) Trading 8.1% Higher – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price traded up 8.1% on Wednesday . The stock traded as high as $19.31 and last traded at $20.07. 368 shares were traded during trading, a decline of 90% from the average session volume of 3,727 shares. The stock had previously closed at $18.56.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, April 13th. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat, Ascentage Pharma Group International presently has a consensus rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Stock Performance

The business’s 50 day moving average is $23.52 and its 200-day moving average is $26.25. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million for the quarter. As a group, analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS Group AG boosted its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter. XY Capital Ltd boosted its stake in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International during the 2nd quarter worth $391,000. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth $383,000. Finally, ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.